Exact Sciences to participate in August investor conference

Go back to Exact Sciences to participate in August investor conference

Evercore on Exact Sciences (EXAS): 'Aetna policy change is not incremental to Cologuard screening interval'

August 1, 2022 3:59 PM EDT

Evercore maintains Outperform on Exact Sciences (NASDAQ: EXAS) and PT $60.00.

Analyst Vijay Kumar comments "Aetna policy change is not incremental to Cologuard screening interval", "We think the Aetna language of 1 to 3 years refers to annual screening for FIT-DNA (which is lower priced) and... More